CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.

MLA

Carreño-Tarragona, Gonzalo, et al. “CNL and ACML Should Be Considered as a Single Entity Based on Molecular Profiles and Outcomes.” Blood Advances, vol. 7, no. 9, May 2023, pp. 1672–81. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022008204.

APA

Carreño-Tarragona, G., Álvarez-Larrán, A., Harrison, C., Martínez-Ávila, J. C., Hernández-Boluda, J. C., Ferrer-Marín, F., Radia, D. H., Mora, E., Francis, S., González-Martínez, T., Goddard, K., Pérez-Encinas, M., Narayanan, S., Raya, J. M., Singh, V., Gutiérrez, X., Toth, P., Amat-Martínez, P., Mcilwaine, L., … Cross, N. C. P. (2023). CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Advances, 7(9), 1672–1681. https://doi.org/10.1182/bloodadvances.2022008204

Chicago

Carreño-Tarragona, Gonzalo, Alberto Álvarez-Larrán, Claire Harrison, José Carlos Martínez-Ávila, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, Deepti H Radia, et al. 2023. “CNL and ACML Should Be Considered as a Single Entity Based on Molecular Profiles and Outcomes.” Blood Advances 7 (9): 1672–81. doi:10.1182/bloodadvances.2022008204.